---
schema_version: "secwatch.filing_event.v1"
accession: "0000950159-24-000103"
form_type: "8-K"
ticker: "CI"
cik: "0001739940"
company_name: "Cigna Group"
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:41:57.775872+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cigna raises long-term adjusted EPS growth target to 10%-14%; reaffirms FY2024 guidance of at least $28.25

## Summary
- Long-term average annual adjusted EPS growth target raised to 10%-14% from prior target.
- 2024 adjusted EPS guidance reaffirmed at least $28.25 per share.
- Launches EncircleRx: industry-first financial guarantee for GLP-1s to help cap employer costs.
- Evernorth Behavioral Care Group launched; guarantees appointment within 72 hours, scales by 2025.
- Evernorth plans Humira biosimilar at $0 out-of-pocket for eligible Accredo patients by end of 2024.

## SEC filing metadata
- accession: 0000950159-24-000103
- form_type: 8-K
- ticker: CI
- cik: 0001739940
- company_name: Cigna Group
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739940/000095015924000103/0000950159-24-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739940/000095015924000103/cigna8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950159-24-000103
- JSON: https://secwatch.observer/filing/0000950159-24-000103.json
- Plain text: https://secwatch.observer/filing/0000950159-24-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.